Lebrikizumab (Ebglyss)
Almirall
Description
A subcutaneous injection of the monoclonal antibody lebrikizumab for the treatment of moderate-to-severe psoriasis.
Indications
Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older with a body weight of at least 40kg who are candidates for systemic therapy.
Contraindications
Hypersensitivity to the active substance or to any of the excipients
Price
Two 250mg solutions for injection in pre-filled syringes or pens, £2271.26
More on: Systemic eczema treatments